A huge thank you to @shafiarahman_ & @RischZack for presenting us with the latest data in #EGFR targeting in #metastatic #ColorectalCancer.

Excited to see how 🩸🧬#ctDNA can help us design rational strategies to better use EGFR therapies particularly with re-challenge.
---
RT @JohnEbbenMDPhD
@TumorBoardTues @shafiarahman_ @RischZack @MPishvaian @ColonCancerCoal @colontown @coloncancermike @GlobalCRC 3/6 #TumorBoardTuesday
🎥 TBT in a…
https://twitter.com/JohnEbbenMDPhD/status/1639072110139125761

A huge thank you to the one and only @DrSteveMartin & @DAielloMD for bringing us the #MarchMadness of #NSCLC and exploring how #ctDNA will change practice! I'm looking forward to that baklava!
---
RT @JohnEbbenMDPhD
@TumorBoardTues @DrSteveMartin @DAielloMD @MPishvaian @NarjustFlorezMD @EGFRResisters @lcrf_org @ADesaiMD @GDutcherMD 3/5 #TumorBoardTuesday
Thurs Case🎀

🎥 TBT in a video
ctDNA + tissue-based NGS= highest sensitivity (do…
https://twitter.com/JohnEbbenMDPhD/status/1634012967149920257

RT @CharuAggarwalMD
@DrSteveMartin @TumorBoardTues @MPishvaian @DAielloMD @JohnEbbenMDPhD @ChristianRolfo Given that oncogenic drivers are mutually exclusive (majority of the time), finding of a non-actionable mutation such as KRAS G12D can be immensely meaningful, to begin therapy which is #MolecularlyInformed #ctDNA

It's TIME! Follow the thread below as #TumorBoardTuesday, led by @DrSteveMartin & @DAielloMD discuss real 🌎 examples of #ctDNA use in #NSCLC. Can't wait to learn 📚 from these cases!
---
RT @DAielloMD
1/26 #TumorBoardTuesday #LungCancer #OncTwitter @DrSteveMartin
⛹🏻‍♀️Case 1⛹️‍♂️
80 yo 👵🏼 never 🚬
🩻 Imaging shows R lung mass
🦴 New hip pain found to have R femoral lytic lesion
⚒️Undergoes ORIF R femur
🔬R femur path: metastatic squamous cel…
https://twitter.com/DAielloMD/status/1633271395550412800

RT @OncBrothers@twitter.com

4. #ctDNA kinetics in CRC: How and when to incorporate ctDNA in our clinics and what to make out of the levels:

- cfDNA concentration did not impact ctDNA detection
- Can start testing for MRD from week 2 of surgery

https://twitter.com/OncoJurdi/status/1615400556675096576

https://twitter.com/pashtoonkasi/status/1616884460162797570

🐦🔗: https://twitter.com/OncBrothers/status/1616940789128462337

RT @OncBrothers@twitter.com

Day 3 #GI23 Highlights #CommunityOncology

1. #MOUNTAINEER: Tucat+Trast approved CRC

2. #SUNLIGHT: TAS102+Bev confirmed late option CRC

3. #E2211: Cape+Tem in pNET manuscript

4. #ctDNA kinetics CRC

5. TNT state in RectalCA

@ASCO@twitter.com #OncEd #MedEd @OncoAlert@twitter.com #GISM #MedTwitter

🐦🔗: https://twitter.com/OncBrothers/status/1616940781562134534

RT @benweinbergmd@twitter.com

#ctDNA kinetics!!🩸🩸🩸🧬🧬🧬
Over 14k stage I-III #coloncancer patients tested 0-12 weeks post-op ➡️ 2-8 week time window appears to be ideal for MRD testing, higher cfDNA early on didn't hurt ctDNA detection @ASCO@twitter.com #GI23 @OncoAlert@twitter.com

🐦🔗: https://twitter.com/benweinbergmd/status/1616878397736583169

RT @manjuggm@twitter.com

Circulating Tumor DNA: Prime Time or Jumping Too Soon?
#GI23 @ASCO@twitter.com with Dr @JeanneTie@twitter.com
Early stage CRC CtDNA(+) patients without chemo=> not good!
The audience seems to agree that the patient needs chemo!
#ctDNA

🐦🔗: https://twitter.com/manjuggm/status/1616834273310560256

RT @manjuggm@twitter.com

Circulating Tumor DNA: Prime Time or Jumping Too Soon?
#GI23 @ASCO@twitter.com with Dr @JeanneTie@twitter.com
Nice polls! #CtDNA
"The VAFs shows the extent of disease"

🐦🔗: https://twitter.com/manjuggm/status/1616833527311634432

RT @pashtoonkasi@twitter.com

@RenoHemonc@twitter.com Great question as #GI23 is starting. It’s a new setting. 2 thoughts:

In the absence of a standard, do what a trial did/is doing.👇🏾6 months should be reasonable. Use #ctDNA to assess MRD.

⚠️Careful with the stenosis from the exquisite response. May require intervention/surgery.

🐦🔗: https://twitter.com/pashtoonkasi/status/1615863480304664579

RT @IbrahimSahinMD1@twitter.com

✳️Another interesting finding is that 20% patients who did not clear #ctDNA remained disease free over 12 months ‼️
✳️This means ctDNA dynamics and recurrence are not independent from disease biology ❗️

🐦🔗: https://twitter.com/IbrahimSahinMD1/status/1615812819303436288

RT @IbrahimSahinMD1@twitter.com

Some interesting findings of Galaxy trials from my view :
✳️Cumulative clearance rate was high but then even 19% of those who cleared #ctDNA, had disease recurrence in 18 months ‼️
✳️This means ctDNA clearance does not always mean a cure, rather just undetectable ❗️@OncoAlert@twitter.com

🐦🔗: https://twitter.com/IbrahimSahinMD1/status/1615812803914526723

RT @pashtoonkasi@twitter.com

@Aiims1742@twitter.com @skopetz@twitter.com Looks like the #GI23 party has already started🎉.

@Aiims1742@twitter.com In addition to the #ctDNA🩸🧬hazard ratios, what I’m really excited about in this abstract is that we show NO significant impact of plasma

📉cfDNA levels on
📈ctDNA detection rates

More🔜.
https://meetings.asco.org/abstracts-presentations/215766

🐦🔗: https://twitter.com/pashtoonkasi/status/1615503001002672130

RT @pashtoonkasi@twitter.com

🆕 🗞️#GI23 hasn’t started and we already have a very relevant #Tweetorial from the earlier oral presentation @ASCO@twitter.com #GI22 now published @NatureMedicine@twitter.com.

👇🏾The Galaxy 🌌 arm of the CIRCULATE 🇯🇵.

Rich data on a large cohort to learn from. ➡️Impact on ongoing trials.

#ctDNA🩸🧬 https://twitter.com/oncojurdi/status/1615400556675096576

🐦🔗: https://twitter.com/pashtoonkasi/status/1615508172436914176

RT @OncoJurdi@twitter.com

GALAXY arm from CIRCULATE-JAPAN just published in @NatureMedicine@twitter.com reporting #ctDNA #MRD and efficacy of adjuvant chemotherapy in patients with colorectal cancer with 18 month DFS. https://rdcu.be/c3zoC
a🧵

🐦🔗: https://twitter.com/OncoJurdi/status/1615400556675096576

RT @aaleshin@twitter.com

This publication is a big milestone for the countless investigators, researchers, and lab scientists who participated. Big thanks to Dr Yoshino and the NCCE in Japan for their vision to start this study, and most importantly for all the patients who participated. #ctDNA $NTRA

🐦🔗: https://twitter.com/aaleshin/status/1615080133702082561

RT @aaleshin@twitter.com

New GALAXY data published by Drs Kotani and Yoshino in #Nature Medicine. (1) ctDNA is most prognostic factor for DFS (2) ACT in ctDNA (+) pts associated w/ improved DFS, but NOT in ctDNA (-) (3) ctDNA dynamics -> tx efficacy #ctDNA #CRC #Natera #Signatera
https://www.nature.com/articles/s41591-022-02115-4

🐦🔗: https://twitter.com/aaleshin/status/1615080112193687552

RT @manjuggm@twitter.com

Tagging Drs @PrajnanDasMD@twitter.com @DrJZell@twitter.com @skopetz@twitter.com @CathyEngMD@twitter.com @JeanneTie@twitter.com @pashtoonkasi@twitter.com @IbrahimSahinMD1@twitter.com

#ctDNA #CRCSM
https://www.ejcancer.com/article/S0959-8049(22)01803-2/fulltext https://twitter.com/CrcTrialsChat/status/1615060410176049160

🐦🔗: https://twitter.com/manjuggm/status/1615062037645692928

RT @pashtoonkasi@twitter.com

@manjuggm@twitter.com @PrajnanDasMD@twitter.com @DrJZell@twitter.com @skopetz@twitter.com @CathyEngMD@twitter.com @JeanneTie@twitter.com @IbrahimSahinMD1@twitter.com We unveil one of the largest cohorts of #ctDNA🩸🧬 📉📈response assessment in patients with #colorectalcancer.

More details at @ASCO@twitter.com #GI23 🔜!

Can’t wait! 👏🏾

@OncoAlert@twitter.com

https://meetings.asco.org/abstracts-presentations/215962

🐦🔗: https://twitter.com/pashtoonkasi/status/1615066209304674311

RT @CrcTrialsChat@twitter.com

Happy to have Dr. @JeanneTie@twitter.com as the session moderator for the next #CRCTrialsChat focused on #ctDNA in #Colorectalcancer along with Drs @aparna1024@twitter.com @jonathanloree@twitter.com @IbrahimSahinMD1@twitter.com
@VanMorrisMD@twitter.com @adasarimd@twitter.com @doctorC369@twitter.com & @manjuggm@twitter.com. Maybe Dr @TakayukiYoshin5@twitter.com too!
👇👇
Come join us!

🐦🔗: https://twitter.com/CrcTrialsChat/status/1582815769590902785